Mesoblast Ltd Announces New Securities Issue

Ticker: MEOBF · Form: 6-K · Filed: Jan 24, 2025 · CIK: 1345099

Mesoblast LTD 6-K Filing Summary
FieldDetail
CompanyMesoblast LTD (MEOBF)
Form Type6-K
Filed DateJan 24, 2025
Risk Levelmedium
Pages1
Reading Time1 min
Sentimentneutral

Sentiment: neutral

Topics: securities-issue, capital-raise, foreign-private-issuer

Related Tickers: MESO

TL;DR

MESO filing: new securities issue announced Jan 17, 2025. Watch for details.

AI Summary

On January 17, 2025, Mesoblast Limited announced a new securities issue and applied for quotation of these securities on the Australian Securities Exchange. This filing is a report of this foreign private issuer's activities for the month of January 2025.

Why It Matters

This filing indicates Mesoblast Limited is raising capital or restructuring its equity, which could impact its financial position and future operations.

Risk Assessment

Risk Level: medium — New securities issues can signal financial needs or strategic shifts, requiring investors to assess the implications for the company's valuation and future performance.

Key Players & Entities

FAQ

What is the purpose of the new securities issue announced by Mesoblast Limited?

The filing does not specify the purpose of the new securities issue, only that an announcement and application for quotation were made on January 17, 2025.

When was the new issue announcement filed with the Australian Securities Exchange?

The new issue announcement was filed on January 17, 2025.

What form is this SEC filing?

This is a Form 6-K report.

What is Mesoblast Limited's fiscal year end?

Mesoblast Limited's fiscal year ends on June 30.

Where is Mesoblast Limited's principal executive office located?

Mesoblast Limited's principal executive office is located at Level 38, 55 Collins Street, Melbourne, Victoria 3000, Australia.

Filing Stats: 363 words · 1 min read · ~1 pages · Grade level 13.7 · Accepted 2025-01-24 06:34:33

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly organized. Mesoblast Limited s Niva Sivakumar Niva Sivakumar Company Secretary Dated January 24, 2025 INDEX TO EXHIBITS Item 99.1 Appendix 2A of Mesoblast Ltd, dated January 17, 2025 . 99.2 Appendix 3Y of Mesoblast Ltd, dated January 16, 2025 . 99.3 Appendix 2A of Mesoblast Ltd, dated January 22, 2025 . 99.4 Appendix 2A of Mesoblast Ltd, dated January 24, 2025.

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing